Kura Oncology Q2 Product Revenue Jumps 57% on KOMZIFTI Uptake
KURA sits 83% above its 52-week low of $5.52.
Summary
Kura Oncology reported Q2 net product revenue up 57% quarter-over-quarter, driven by accelerating KOMZIFTI uptake in relapsed/refractory NPM1-mutant AML. New patient starts rose 35% from Q1, and the drug captured majority share of new starts in its class. Net loss widened to $68.3 million as R&D and SG&A expenses increased. Management expects sustained quarter-over-quarter growth and expanding physician adoption. Cash runway is projected to fund the ziftomenib AML program through topline Phase 3 results in 2028. This follows the first full quarter of KOMZIFTI revenue at $5.8 million reported in May, indicating strong commercial momentum.
At the time of this announcement, KURA was trading at $10.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $882.4M. The 52-week trading range was $5.52 to $12.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.